Skip to main content

Table 3 Comparison of antimicrobial regimens in hospitalized elderly CAP patients with clinical failure and clinical success (n = 3011)

From: Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patients

Regimen

CF(n = 395)

CS(n = 2616)

p value

Consistent with guideline

115 (29.1)

1032 (39.4)

<0.001

β-lactam

76 (19.2)

579 (22.1)

 

Fluoroquinolone

22 (5.6)

368 (14.1)

 

β-lactam + macrolide

6 (1.5)

74 (2.8)

 

β-lactam + fluoroquinolone

22 (5.6)

11 (0.4)

 

Undertreated by guideline

138 (34.9)

396 (15.1)

<0.001

β-lactam

99 (25.1)

302 (11.5)

 

β-lactam + macrolide

8 (2.0)

42 (1.6)

 

Macrolide

1 (0.3)

18 (0.7)

 

Fluoroquinolone +/− β-lactam/other

18 (4.6)

17 (0.6)

 

Other combination

12 (3.0)

17 (0.6)

 

Overtreated by guideline

142 (35.9)

1188 (45.4)

<0.001

Antipseudomonal β-lactam

47 (11.9)

468 (17.9)

 

Fluoroquinolone +β-lactam/ other

71 (18.0)

585 (22.4)

 

Antipseudomonal β-lactam+ macrolide

6 (1.5)

45 (1.7)

 

Antipseudomonal β-lactam + other

11 (2.8)

52 (2.0)

 

Fluoroquinolone + macrolide

0 (0)

17 (0.6)

 

β-lactam +quinolone+ other

5 (1.3)

11 (0.4)

 

β-lactam +macrolide+ fluoroquinolone /other

2 (0.5)

10 (0.4)

 
  1. Note: other = imidazoles, lincomycin, etracyclines, aminoglycoside, fosfomycin, glycopeptides and antifungal agents